Epidermolysis bullosa dystrophica
MONDO:0006543A genetic skin disorder caused by mutations in the type VII collagen gene (COL7A1). It is characterized by the formation of blisters and scarring in the skin and mucous membranes.
Also known as: DEB, dermolytic epidermolysis bullosa, epidermolysis bullosa dystrophica, epidermolysis bullosa, dermolytic
30 clinical trials for this condition and its sub-types, 23 tagged with Epidermolysis bullosa dystrophica itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Epidermolysis bullosa dystrophica
-
1 sub-type
-
Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
Disease control Not yet recruitingThis trial evaluates a gene therapy skin graft called prademagene zamikeracel (pz-cel) for treating wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic condition that causes fragile skin and chronic wounds. The study includes three parts: one…
Phase 4 • Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase 1/2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Anti-Inflammatory drug may ease swallowing in rare skin disease
Symptom relief Not yet recruitingThis study investigates whether budesonide, an anti-inflammatory medication, can improve swallowing difficulties in people with dystrophic epidermolysis bullosa, a rare genetic condition that causes fragile skin and scarring. The researchers will review medical records of 15 pati…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC